Medicine
Adverse Drug Event Reporting
The Roles of Consumers and Health-Care Professionals: Workshop Summary
by Forum on Drug Discovery, Development, and Translation, Jeffrey M. Drazen, Jennifer Rainey, Heather Begg, and Adrienne Stith Butler, Rapporteurs
Description
Recent concerns about the unexpected adverse effects of marketed drugs, such as COX-2 (cyclooxygenase-2) inhibitors or specific statins, raise concerns not only about reporting these events during premarket studies, but also about the responsibility for ongoing surveillance of drugs once they are on the market. Sometimes serious adverse drug reactions are fully appreciated only after a drug has been on the market for years. Therefore, when a drug is approved and released to the market, large numbers of patients will be exposed before all the potential adverse effects have been identified and thoroughly studied. Currently, there is no clearly defined process for addressing safety questions about drugs after premarketing research has occurred. In November 2005, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation convened a workshop to explore issues associated with the reporting of ADEs. The workshop addressed the following questions: How can ADEs be effectively identified, particularly when the adverse effects are rare? How can the direct, causal effects of drugs be distinguished from simple associations? How can health-care professionals and their patients' aid in the identification of drug-related adverse events? How can knowledge of ADEs be more effectively used in clinical practice? Adverse Drug Event Reporting reviews current sources of information on adverse drug events, including the FDA's MedWatch program and the AERS, institutional review boards, and the CMS. This report considers the ways that consumers and advocacy groups can be involved in reporting adverse events, and discusses drug interactions, problems with current databases for capturing and evaluating interactions, and difficulties in communicating information about adverse drug interactions. This report also describes new requirements for information contained on drug labels and how labels can be used to communicate information about risks and drug interactions to consumers and practitioners.
More Information
Rights Information
WW ex JP, CN, KR ; L
Marketing Information
http://www.nap.edu/11897
National Academies Press
The National Academies Press (NAP) publish the reports of the National Academies of Sciences, Engineering and Medicine. They published more than 200 books a year on a wide range of topics.
View all titlesBibliographic Information
- Publisher National Academies Press
- Publication Date April 2007
- Orginal LanguageEnglish
- ISBN/Identifier 9780309102766
- Publication Country or regionUnited States
- FormatPaperback
- Primary Price 21 USD
- Pages82
- ReadershipProfessional and scholarly
- Publish StatusPublished
- Dimensions9 x 6 inches
- Biblio Notes2007
Thank you for proceeding with this offer.
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
Please wait while the payment is being prepared.
Do not close this window.
(c) Copyright 2024 - Frankfurt Rights. All Right Reserved